W B van den Berg Selected Research

Arthritis (Polyarthritis)

12/2007	Application of a disease-regulated promoter is a safer mode of local IL-4 gene therapy for arthritis.
04/2007	GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice.
03/2007	Toll-like receptor 4 induced FcgammaR expression potentiates early onset of joint inflammation and cartilage destruction during immune complex arthritis: Toll-like receptor 4 largely regulates FcgammaR expression by interleukin 10.
11/2006	Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.
04/2004	Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis.
01/2003	Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis.
09/2002	Is there a rationale for combined TNF and IL-1 blocking in arthritis?
03/2002	Local overexpression of adeno-viral IL-4 protects cartilage from metallo proteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs.
12/2001	Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis.
11/2001	Uptake of apoptotic leukocytes by synovial lining macrophages inhibits immune complex-mediated arthritis.
11/2000	Arguments for interleukin 1 as a target in chronic arthritis.
04/2000	Role of Fc receptor gamma chain in inflammation and cartilage damage during experimental antigen-induced arthritis.
03/2000	Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic, and radiologic signs of type II collagen-induced arthritis.

Articles by Research Topic

Disease

13	Arthritis (Polyarthritis) 12/2007 - 03/2000
10	Rheumatoid Arthritis 12/2005 - 09/2000
9	Experimental Arthritis 09/2008 - 07/2001
7	Inflammation 09/2008 - 04/2000
4	Osteophyte 12/2007 - 02/2001
4	Osteoarthritis 12/2007 - 01/2000
2	Necrosis 11/2006 - 07/2001

Drug/Important Bio-Agent (IBA)

7	Interleukin-1 (Interleukin 1)IBA 11/2006 - 11/2000
5	Transforming Growth Factor beta (TGF-beta)IBA 12/2007 - 01/2000
5	IgG Receptors (Fc gamma RI)IBA 12/2005 - 12/2001
4	Antigen-Antibody Complex (Immune Complex)IBA 03/2007 - 11/2001
3	Collagen Type II (Type II Collagen)IBA 04/2004 - 03/2000
2	Interleukin-4 (Interleukin 4)IBA 12/2007 - 03/2002
2	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2005 - 08/2005
2	Interleukin-1 Receptor Accessory ProteinIBA 07/2005 - 10/2003
2	CytokinesIBA 06/2004 - 11/2001
2	Interleukin-17 (Interleukin 27)IBA 02/2002 - 07/2001
2	AntigensIBA 12/2001 - 04/2000
1	Carbon MonoxideIBA 09/2008
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2007
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 04/2007
1	Toll-Like Receptor 4IBA 03/2007
1	Interleukin-10 (Interleukin 10)IBA 03/2007
1	InterleukinsIBA 11/2006
1	Interleukin-13IBA 12/2005
1	Cysteine (L-Cysteine)FDA Link 03/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2005
1	GlucocorticoidsIBA 04/2004
1	Carrier Proteins (Binding Protein)IBA 06/2003
1	Interleukin-18 (Interleukin 18)IBA 06/2003
1	Matrix MetalloproteinasesIBA 03/2002
1	Interleukin-1beta (Interleukin 1 beta)IBA 10/2001
1	Interferon-gamma (Interferon, gamma)IBA 10/2001
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 02/2001
1	Clodronic Acid (Clodronate)IBA 09/2000
1	Liposomes (Liposome)IBA 09/2000
1	Fc Receptors (Fc Receptor)IBA 04/2000